Form 4: Gilead Director Sells Shares After Option Exercise

Gilead Sciences Director Kelly A. Kramer exercised stock options and subsequently sold common stock under a Rule 10b5-1 trading plan.

Summary

• Kelly A. Kramer, a Director at Gilead Sciences, Inc. (GILD), engaged in transactions involving the exercise of non-qualified stock options and the subsequent sale of common stock.
• The transactions occurred on November 26, 2025, and November 28, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2025.
• On November 26, 2025, Kramer exercised options to acquire 2,806 shares of common stock at an exercise price of $81 per share and immediately sold these 2,806 shares at $127.11 per share.
• On November 28, 2025, Kramer exercised options to acquire 2,805 shares of common stock at an exercise price of $81 per share and immediately sold these 2,805 shares at $127.10 per share.
• The options were fully vested on August 19, 2017, and had an expiration date of August 19, 2026.
• Following these transactions, Kramer's direct beneficial ownership of common stock is 1,339 shares, and 0 derivative securities (options) from these specific grants.

Sentiment

Score: 6

Explanation: The transactions represent a routine, pre-planned exercise of stock options and subsequent sale of shares by a director, indicating a personal financial decision rather than a change in company outlook. The transactions were executed at a significant profit for the insider, which is a positive for the individual.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and compliant approach to insider trading.
• The sale prices of $127.11 and $127.10 per share are significantly higher than the option exercise price of $81, resulting in a substantial profit for the reporting person.

Negatives

• The transactions represent insider selling, which, while planned, reduces the director's direct equity stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction, which is common across all industries as part of executive compensation and personal financial planning. It does not provide specific insights into broader industry trends or competitive positioning for Gilead Sciences.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, slightly dilutes the director's direct alignment with shareholder interests, though the volume is not significant enough to cause concern.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise of options and sale of shares) by a director. Such transactions are common for executive compensation and personal financial planning and typically do not reflect a change in the company's fundamental outlook or performance. Therefore, it does not provide new information that would warrant a change in investment recommendation for Gilead Sciences.

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Director, Equity Sales